Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
Abstract Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that efficiently delivers a highly potent microtubule inhibitor to HER2 overexpressing cells. Herein, we utilize HER2 transformed human mammary epithelial cells (HME2) to demonstrate in vitro and in vivo response and recurren...
Guardado en:
Autores principales: | Saeed S. Akhand, Hao Chen, Stephen Connor Purdy, Zian Liu, Joshua C. Anderson, Christopher D. Willey, Michael K. Wendt |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c221eeac5a54468f97d9820efc707149 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014) -
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014) -
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
por: Olav Engebraaten, et al.
Publicado: (2021) -
Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
por: Samy Hakroush, et al.
Publicado: (2021) -
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)